REGENERX BIOPHARMACEUTICALS INC
DelistedCIK 707511fmd_0REPYYTD3ME4MKNVHZEN8AHHPHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Mar 31, 2023, 52 periods
Latest annual · FY2022
Millions- Total revenues
- 0
- Operating income
- (1)
- Net income
- (2)
Latest quarter · Q1 FY2023
Millions- Total revenues
- 0
- Operating income
- (0)
- Net income
- (0)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2019 to FY2022
- 0.0%
- Revenue, 5 yearsFY2017 to FY2022
- +6.3%
- Net income, 5 yearsFY2017 to FY2022
- n/m
REGENERX BIOPHARMACEUTICALS INC financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Revenue | $76,761 | $76,761 | 0% | 10-K 2023-04-11 · proof |
| Operating income | -$1.4 million | -$1.3 million | 10-K 2023-04-11 · proof | |
| Net income | -$1.7 million | -$1.6 million | 10-K 2023-04-11 · proof | |
| Cash from operating activities | -$940,718 | -$990,296 | 10-K 2023-04-11 · proof | |
| Total assets | $382,177 | $1.3 million | -70.3% | 10-K 2023-04-11 · proof |
| Total liabilities | $3.8 million | $3.5 million | +8.9% | 10-K 2023-04-11 · proof |
| Cash and cash equivalents | $290,890 | $1.2 million | -76.4% | 10-K 2023-04-11 · proof |
- What was REGENERX BIOPHARMACEUTICALS INC's revenue in fiscal 2022?
- REGENERX BIOPHARMACEUTICALS INC reported revenue of $76,761 for fiscal 2022 (the year ended Dec 31, 2022), against $76,761 the year before (0%). Source: the 10-K filed with the SEC on Apr 11, 2023. SEC
- What was REGENERX BIOPHARMACEUTICALS INC's operating income in fiscal 2022?
- REGENERX BIOPHARMACEUTICALS INC reported operating income of -$1.4 million for fiscal 2022 (the year ended Dec 31, 2022), against -$1.3 million the year before. Source: the 10-K filed with the SEC on Apr 11, 2023. SEC
- What was REGENERX BIOPHARMACEUTICALS INC's net income in fiscal 2022?
- REGENERX BIOPHARMACEUTICALS INC reported net income of -$1.7 million for fiscal 2022 (the year ended Dec 31, 2022), against -$1.6 million the year before. Source: the 10-K filed with the SEC on Apr 11, 2023. SEC
- What was REGENERX BIOPHARMACEUTICALS INC's cash from operating activities in fiscal 2022?
- REGENERX BIOPHARMACEUTICALS INC reported cash from operating activities of -$940,718 for fiscal 2022 (the year ended Dec 31, 2022), against -$990,296 the year before. Source: the 10-K filed with the SEC on Apr 11, 2023. SEC
- What are REGENERX BIOPHARMACEUTICALS INC's total assets?
- As of Dec 31, 2022, REGENERX BIOPHARMACEUTICALS INC reported total assets of $382,177, against $1.3 million a year earlier (-70.3%). Source: the 10-K filed with the SEC on Apr 11, 2023. SEC
- What are REGENERX BIOPHARMACEUTICALS INC's total liabilities?
- As of Dec 31, 2022, REGENERX BIOPHARMACEUTICALS INC reported total liabilities of $3.8 million, against $3.5 million a year earlier (+8.9%). Source: the 10-K filed with the SEC on Apr 11, 2023. SEC
- What are REGENERX BIOPHARMACEUTICALS INC's cash and cash equivalents?
- As of Dec 31, 2022, REGENERX BIOPHARMACEUTICALS INC reported cash and cash equivalents of $290,890, against $1.2 million a year earlier (-76.4%). Source: the 10-K filed with the SEC on Apr 11, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:707511&period_type=annual&limit=5"Information only, not investment advice.